Senti Biosciences, Inc.
$2.39
-6.2%Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -0.3).
Valuation inputs: P/E -0.3, earnings yield N/A, momentum -6.2%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -2.1%, ROIC -68.2%).
Profitability stack: net margin 0.0%, ROE -2.1%, ROIC -68.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceDownside profile is elevated and scenario stress-testing is essential.
Risk factors: liabilities/assets +73.8%, momentum -6.2%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Senti Biosciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Senti Biosciences, Inc. Fair Value Envelope
Senti Biosciences, Inc. Profit Bridge
Profitability Analysis
Senti Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Senti Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Debt-to-Equity Ratio
High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Senti Biosciences, Inc. Street Expectations Map
Wall Street analysts project that SNTI stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 6.00, with estimates ranging from a low of 6.00 to a high of 6.00.
The consensus 1-year price target stands at 6.00, with estimates ranging from a low of 6.00 to a high of 6.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Senti Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $270K worth of SNTI shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
131.7K
269.98K
0
0.00
+270K
+$270K
Top Buyers
Tang Donald F
Director
$45K
Collins James J.
Director
$45K
Cooperstone Brenda
Director
$45K
Hsiung Feng
Director
$45K
Schulz Fran
Director
$45K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $270K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
snti Dividend History
Learning Layer
Related Guides
Build conviction on SNTI by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.